L. Mahjoubi

发表

Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.

J. Pignon, M. Ducreux, V. Boige, 2020, European journal of cancer.

3 1 . 1 Immune Checkpoints

N. Rizvi, A. Marabelle, L. Mahjoubi, 2018 .

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

J. Adam, J. Soria, C. Caramella, 2017, European journal of cancer.

Rare metastasis to the iris from renal cell carcinoma responds to an anti-angiogenic therapy – a case report

V. Molinie, H. Merle, L. Mahjoubi, 2014 .

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica

C. Sternberg, M. Ducreux, J. Adam, 2018, Tumori.

Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient

S. de Botton, P. Woerther, E. Chachaty, 2017, Infection.

New insights into the role of EMT in tumor immune escape

J. Thiery, S. Terry, P. Saintigny, 2017, Molecular oncology.

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib

J. Soria, L. Lacroix, B. Besse, 2016, Investigational New Drugs.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

D. Planchard, F. André, J. Soria, 2016, Clinical Cancer Research.

Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study

J. Thiery, E. Solary, A. Eggermont, 2019, Experimental and Molecular Therapeutics.

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

E. Solary, D. Planchard, A. Eggermont, 2020, npj Precision Oncology.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

J. Soria, M. Schlumberger, C. Robert, 2016, European journal of cancer.

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

J. Soria, B. Doger, V. Boni, 2018, European journal of cancer.

Profile and outcome of cancer patients enrolled in contemporary phase I trials.

Y. Loriot, V. Ribrag, S. Ammari, 2023, European Journal of Cancer.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

J. Thiery, E. Solary, D. Planchard, 2019, Clinical Cancer Research.

Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population

J. Sabourin, V. Vinh-Hung, V. Molinie, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.